Publications by authors named "Michael A Farber"
Brief Report: A Novel Digital Therapeutic that Combines Applied Behavior Analysis with Gaze-Contingent Eye Tracking to Improve Emotion Recognition in Children with Autism Spectrum Disorder.
J Autism Dev Disord
May 2022
Article Synopsis
- This study explored a digital game called Lookware™, designed to help children with autism spectrum disorder (ASD) improve their emotion recognition skills using behavior analysis and eye tracking.
- Children aged 4-14 were split into two groups: one played Lookware™ while the other played a control game.
- Results showed that those who played Lookware™ had significantly better emotion recognition skills after the program, and both children and staff found the game to be feasible and acceptable.
Article Synopsis
- Heart failure (HF) can occur in hypertensive patients with either preserved (HFPEF) or reduced (HFREF) left ventricular ejection fraction, and the ALLHAT trial evaluated treatment effects on these conditions.
- Chlorthalidone was found to significantly lower the risk of both HFPEF and HFREF compared to other medications like amlodipine, lisinopril, and doxazosin.
- Mortality rates were higher in patients with HFREF compared to those with HFPEF after diagnosis, indicating differing outcomes based on the type of heart failure.
Background: Chronic kidney disease is common in older patients with hypertension.
Objective: To compare rates of coronary heart disease (CHD) and end-stage renal disease (ESRD) events; to determine whether glomerular filtration rate (GFR) independently predicts risk for CHD; and to report the efficacy of first-step treatment with a calcium-channel blocker (amlodipine) or an angiotensin-converting enzyme inhibitor (lisinopril), each compared with a diuretic (chlorthalidone), in modifying cardiovascular disease (CVD) outcomes in high-risk patients with hypertension stratified by GFR.
Design: Post hoc subgroup analysis.
Background: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial reported that treatment initiated with doxazosin compared with chlorthalidone doubled the risk for heart failure in high-risk hypertensive patients (relative risk, 2.04 [95% CI, 1.79 to 2.
View Article and Find Full Text PDF